Sugemalimab: First Approval
Sign Up to like & getrecommendations! Published in 2022 at "Drugs"
DOI: 10.1007/s40265-022-01693-4
Abstract: Sugemalimab (Cejemly® in China) is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb) that is being developed by CStone Pharmaceuticals for the treatment of advanced solid tumours… read more here.
Keywords: cancer; first approval; sugemalimab; treatment ... See more keywords